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Effects of Topically Applied Acitretin in
Reconstructed Human Epidermis and the Rhino
Mouse
Edward Hsia1, Michael J. Johnston2, Robert J. Houlden2, Wendy H. Chern1 and Hans E.J. Hofland1
Oral acitretin is currently indicated for the treatment of severe psoriasis in adults, but its use is limited by
systemic side effects and teratogenicity. Topical administration of acitretin may lessen the risk of systemic
toxicity while increasing local bioavailability in the skin. The effects of topical acitretin on reconstructed human
epidermis (RHE) and Rhino mice were investigated and compared to those of currently marketed topical
retinoids: tretinoin and tazarotene. In acitretin-treated RHE cultures, there was a reduction in keratohyalin
granules and filaggrin expression in the stratum granulosum, a loss of keratin 10 expression in the stratum
spinosum, and an increase in keratin 19 expression in all viable cell layers. All retinoids showed similar signs of
activity in RHE cultures. Furthermore, the release of pro-inflammatory cytokines IL-1a and IL-8 in RHE cultures
was less pronounced with acitretin compared to tretinoin- and tazarotene-containing formulations, suggesting
that acitretin may be less irritating. In Rhino mice, acitretin induced a local, dose-dependent reduction in utricle
diameter after seven daily dermal doses. A similar effect was observed in tretinoin- and tazarotene-treated mice.
Our data suggest that topical application of acitretin may have a therapeutic benefit in the local management of
keratinization disorders.
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INTRODUCTION
Retinoids are known to influence keratinocyte differen-
tiation and have proven to be effective in the treatment of
a variety of disorders of keratinization (Zouboulis, 2001).
The mechanism of action of retinoids, such as all-trans-
retinoic acid (tretinoin), occurs through their interaction with
nuclear retinoic acid receptors (RARs), leading to subsequent
gene expression via retinoic acid response elements (Idres
et al., 2002). The binding affinity of retinoids to various
RAR subtypes (a, b, or g) is thought to contribute to their
relative potency. RARg is the predominant subtype in human
epidermis (Fisher et al., 1994).
Binding of tretinoin to RARs is modulated by the cellular
retinoic acid binding proteins (CRABPs): CRABP I and CRABP
II (Donovan et al., 1995). CRABP II is expressed in the skin
and regulates nuclear levels of tretinoin by sequestration and/
or promotion of its metabolism (Boylan and Gudas, 1992;
Fiorella and Napoli, 1994). Acitretin, an aromatic synthetic
retinoid, has relatively low affinity for RARs, but high affinity
for CRABPs (Norris et al., 1994), and has been shown
to induce a shift in tretinoin binding from CRABPs to RARg
heterocomplexes (Tian et al., 1997). This suggests that acit-
retin causes a redistribution of endogenous tretinoin from
cytoplasmic to nuclear compartments, thereby indirectly
potentiating retinoid activity.
Oral administration of acitretin has been shown to provide
therapeutic benefit for the treatment of psoriasis (Lebwohl
et al., 2001; Lee and Koo, 2005). It has been marketed for
clinical use since 1997 for the treatment of severe psoriasis,
and its safety profile is well characterized. It is known to be
teratogenic, which limits its use (Kistler and Hummler, 1985;
Reiners et al., 1988; Gollnick, 1996).
The clinical efficacy of acitretin following topical appli-
cation in treating cutaneous diseases is as yet unknown.
Percutaneous absorption studies in animals as well as
humans have demonstrated that topical application of
acitretin can produce dermal concentrations that exceed
those achieved with oral administration (Surber et al., 1991,
1993a, b). Topical administration of acitretin may increase
the local bioavailability at the site of action (i.e., diseased
skin) while minimizing potential systemic exposure; there-
fore, it would potentially provide a safer treatment for
keratinization disorders of the skin.
The main objective of this study was to investigate the
potential of acitretin as a topical therapy. Therefore, acitretin
activity was benchmarked against commercially available,
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clinically proven, topical retinoid products. Where possible,
direct comparisons between acitretin and other retinoids
were made using the same vehicle.
Reconstructed human epidermis (RHE) is a stratified culture
that shares histological features that closely resemble human
epidermis in vivo: basal layer and differentiating spinous,
granular, and cornified layers (Poumay et al., 2004). Tretitoin
has been shown to induce specific changes in tissue morphology
and biomarker expression in RHE and serves as a benchmark for
retinoid effects in this model (Rosdy et al., 1997). Moreover,
these responses to tretitoin in RHE cultures have been shown to
correlate with those observed in normal human skin ex vivo,
thereby validating the use of RHE as a predictive model for the
screening of retinoid activity (Bernard et al., 2002).
The Rhino mouse (RHJ/LeJ) is a strain of the hairless
mouse, whose skin contains keratinized pilosebaceous
structures (horn-filled utriculi). The Rhino mouse utriculi
reduction assay is a well-characterized animal model for the
evaluation of retinoid activity (Kligman and Kligman, 1979;
Mezick et al., 1984). Topically applied retinoids, such as
tretitoin, have been shown to reduce the size of utriculi in the
Rhino mouse skin, and this effect is considered predictive of
retinoid efficacy (Beehler et al., 1995).
The effects of topical acitretin in RHE and Rhino mouse
models were investigated in comparison to topical retinoids
with known clinical efficacy and are presented in this study.
RESULTS
Reconstructed human epidermis
Hematoxylin and eosin. Untreated control cultures feature
intact basal, spinous, granulous, and cornified cell layers, and
the epidermal stratification is orthokeratotic, regular, and
normal. Cells in the stratum basale were polarized vertically,
and numerous keratohyalin granules were detectable in the
stratum granulosum. The RHE cultures treated with acitretin,
tretinoin, and tazarotene showed a loss of keratohyalin
granules in the stratum granulosum (Figure 1), while vehicle-
treated cultures were similar to untreated controls.
Keratin 10. In untreated control cultures, keratin 10 (K10) is
expressed in all suprabasal cell layers. K10 expression was
lower in the stratum spinosum of acitretin-treated RHE
cultures than in untreated controls. A similar decrease in
K10 expression was observed in tretinoin- and tazarotene-
treated tissues (Figure 2).
Keratin 19. Keratin 19 (K19) is absent in untreated cultures.
Treatment with acitretin induced significant expression of
K19 in all viable cell layers (Figure 3), although the amount
was slightly less than that observed in tretinoin- and
tazarotene-treated tissues.
Filaggrin. Filaggrin is normally expressed in the stratum
granulosum. Acitretin-treated RHE cultures displayed a
decreased expression of filaggrin, as did tretinoin- and
tazarotene-treated cultures (Figure 4).
The results described above demonstrate that acitretin
modulated epidermal morphology and expression of specific
biomarkers of keratinocyte differentiation in a manner similar
to that of tretinoin and tazarotene.
Cytokine release. The release of IL-1a and IL-8 in the growth
media of RHE cultures treated topically with 0.02% acitretin
solution was approximately fourfold higher compared to
untreated controls (Po0.01) (Figure 5). IL-1a and IL-8 release
in response to tretinoin and tazarotene was 8- 10-fold higher
than that in untreated controls, suggesting that acitretin may
be less irritating than tretinoin and tazarotene. The cytokine
release in vehicle-treated tissues was similar to that in
untreated controls, indicating that the vehicle itself was not
irritating.
Rhino mouse model
Once-daily topical administration of 0.2% acitretin solution
for 7 days caused a complete (100%) reduction in utricle
diameter, which was similar to that observed in tretinoin- and
tazarotene-treated mice (Figure 6 and Table 1). Treatment
with a lower concentration of acitretin (0.02%) also resulted
in a significant reduction of utriculi, but to a lesser degree.
In females treated with 0.02% acitretin, utriculi diameter
decreased from 90.4718.5mm (sham control) to 2.175.2mm,
whereas in males, utriculi diameter decreased from 123.0712.9
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Figure 1. Morphological comparison of RHE tissues treated topically with
various retinoid formulations. RHE tissues were (a) untreated or treated
with (b) vehicle, (c) acitretin 0.02% solution, (d) tretinoin 0.025% cream,
or (e) tazarotene 0.1% cream, and incubated for 3 days at 371C. Following
this incubation period, tissues were fixed, sectioned, and stained with H&E.
Representative micrographs from triplicate cultures are shown. sc, stratum
corneum; sg, stratum granulosum; ss, stratum spinosum; sb, stratum basale.
Bar¼50 mm.
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to 67.6714.2 mm, representing reductions of 98 and 45% in
females and males, respectively. Treatment with vehicle
solution alone did not induce a significant reduction in
utriculi, demonstrating that the effects of acitretin were
specific. Moreover, utricles from skin biopsies taken from
nontreated sites were similar to sham controls, indicating that
the acitretin effect was local and unlikely to be a result of
systemic absorption (Table 1).
DISCUSSION
The cytotoxicity of various solvents in RHE cultures was
investigated, and the dose of acitretin used in these
experiments (0.02%) was based on its maximum solubility
in a non-cytotoxic solvent, octyldodecanol (data not shown).
The effects of the tretinoin 0.025% cream formulation on
RHE cultures have been well characterized; thus, tretinoin
served as a positive control (Bernard et al., 2002). The
tazarotene formulation has not been previously demon-
strated to induce effects in the RHE model, and served as
an additional comparator control. Because tazarotene is a
proprietary compound, the concentration and formulation
used (0.1% cream) were based on its commercial availability.
Acitretin induced in vitro effects in RHE cultures which
were comparable to those of tretinoin- and tazarotene-treated
cultures. These effects included degranulation, induction of
K19 expression, and reduction of K10 and filaggrin. K19 is
a non-epidermal keratin that is absent in normal human
epidermis. K10 is an early biomarker of epidermal differ-
entiation and is normally expressed in all suprabasal layers
(Poumay et al., 1999; Ekholm and Egelrud, 2000). Filaggrin is
a marker of late-stage keratinocyte differentiation that is
normally expressed in the stratum granulosum. Although the
immunohistochemistry data presented are not quantitative,
these in vitro results suggest that acitretin directly affects
differentiating keratinocytes in a manner similar to other
topical retinoids with well-established dekeratinizing effects.
The release of pro-inflammatory cytokines, IL-1a and
IL-8, in RHE cultures is a well-established biomarker of
acute irritation (de Brugerolle de et al., 1999; Medina et al.,
2001; Tornier et al., 2006). Topical tretinoin and tazarotene
are generally recognized as being clinically effective, but are
known to be associated with dermal irritation, which may
limit their use. In the RHE model, the acitretin solution
appears to be less irritating than the two commercially
available products tested (tretinoin and tazarotene creams),
suggesting that a topical acitretin product, in a non-irritating
vehicle, may strike a more optimal balance between efficacy
and irritation in treating disorders of keratinization, while
minimizing the risk of systemic adverse effects.
The Rhino mouse bioassay has frequently been used to
evaluate the potential efficacy of topical retinoids. Com-
monly prescribed topical retinoids, such as tretinoin and
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Figure 2. K10 expression in RHE cultures treated topically with various
retinoid formulations. RHE tissues were (a) untreated or treated with
(b) vehicle alone, (c) acitretin 0.02% solution, (d) tretinoin 0.025% cream,
or (e) tazarotene 0.1% cream, and incubated for 3 days at 371C. Following
this incubation period, tissues were fixed, sectioned, and stained for K10.
Representative micrographs from triplicate cultures are shown. Bar¼ 50 mm.
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Figure 3. K19 expression in RHE cultures treated topically with various
retinoid formulations. RHE tissues were (a) untreated or treated with
(b) vehicle alone, (c) acitretin 0.02% solution, (d) tretinoin 0.025% cream,
or (e) tazarotene 0.1% cream, and incubated for 3 days at 371C. Following
this incubation period, tissues were fixed, sectioned, and stained for K19.
Representative micrographs from triplicate cultures are shown. Bar¼ 50 mm.
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tazarotene, have shown positive results in the Rhino mouse
bioassay in their commercial formulations (Sakuta and
Kanayama, 2005). The dermal toxicity of various solvents
on Rhino mice was investigated, and the highest dose of
acitretin used in these experiments (0.2%) was based on its
maximum solubility in a non-toxic solvent, dimethyl iso-
sorbide (data not shown). The lower dose of 0.02% acitretin
was chosen in an attempt to demonstrate a concentration-
dependent effect. Tretinoin was diluted in the same solvent
as acitretin, thus allowing for a direct comparison. The
concentration of tretinoin used (0.025%) was chosen on the
basis of its clinically effective dose as well as the results of
previously published studies using this model (Kligman and
Kligman, 1979; Bernerd et al., 1991; Bouclier et al., 1991).
Because tazarotene is a proprietary compound, the concen-
tration and formulation used were based on its commercial
availability. Tazarotene 0.1% has been previously shown
to reduce utriculi diameter in Rhino mice (Sakuta and
Kanayama, 2005).
Topical acitretin induced a localized, dose-dependent
decrease in utricle diameter in Rhino mice, which was
comparable to that of tretinoin- and tazarotene-treated
animals. There was no significant increase in epidermal
hyperplasia, indicating that dermal inflammation did not
significantly contribute to utriculi reduction. Utricle reduc-
tion appeared to be sex dependent, which was surprising as
this effect has not been reported in previous studies involving
male and female Rhino mice (Bouclier et al., 1991). More
studies are required to confirm this observation.
Orally administered acitretin has been used for over
10 years in the treatment of severe psoriasis. Although
acitretin has been proven to be effective, concerns about
potential side effects associated with its systemic absorption
have limited its use. Topical administration of acitretin may
reduce the risk of systemic exposure, with a potential to
increase local efficacy in the treated skin disease area. We
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Figure 4. Filaggrin expression in RHE cultures treated topically with various
retinoid formulations. RHE tissues were (a) untreated or treated with (b) vehicle
alone, (c) acitretin 0.02% solution, (d) tretinoin 0.025% cream, or (e) tazarotene
0.1% cream, and incubated for 3 days at 371C. Following this incubation
period, tissues were fixed, sectioned, and immunostained for filaggrin.
Representative micrographs from triplicate cultures are shown. Bar¼ 50mm.
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Figure 5. Release of IL-1a and IL-8 from RHE cultures treated topically with
various retinoid formulations. Triplicate RHE cultures were treated with
various retinoid formulations and incubated for 3 days at 371C. At the end of
this incubation period, concentrations of IL-1a and IL-8 in the media were
determined by ELISA. Values are mean7SD, *Po0.05 (t-test) compared to
untreated control.
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Figure 6. Utriculi of Rhino mice treated topically with various retinoid
formulations. Rhino mice (n¼ 6 per group) were dosed topically once daily
for 7 consecutive days with (a) water, (b) vehicle alone, (c) acitretin 0.02%
solution, (d) acitretin 0.2% solution, (e) tretinoin 0.025% solution,
or (f) tazarotene 0.1% cream. Tissues were fixed, sectioned, and stained
with H&E. Representative micrographs are shown. Bar¼100 mm.
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demonstrated that acitretin can induce dekeratinizing effects
in vitro and in vivo when applied topically; therefore, it may
be effective in treating skin diseases involving abnormal
keratinization.
MATERIALS AND METHODS
Reconstructed human epidermis model
RHE cultures were purchased from SkinEthic Laboratories (Nice,
France). The cultures were maintained in chemically defined growth
medium MCDB 153, containing 5mg/ml insulin, 1.5 mM calcium
chloride, 25 mg/ml gentamycin, and 1 ng/ml EGF. The preparation
and characterization of these cultures have been described
previously (Rosdy et al., 1997). Briefly, a fully differentiated
epidermis was obtained by culturing primary keratinocytes, isolated
from normal human foreskin and cultured on an inert microporous
polycarbonate filter at the air–liquid interface for 14 days. The
following test articles were applied topically at 5ml/0.5 cm2 to
triplicate RHE tissues and incubated for 3 days at 371C/5% CO2:
acitretin (Roche, Basel, Switzerland) 0.02% dissolved in octyldode-
canol (Cognis, Cincinnati, OH; 0.02% was the maximal amount
of acitretin soluble in octyldodecanol), tretinoin cream 0.025%
(Ortho Dermatological, Skillman, NJ), and tazarotene cream 0.1%
(Allergan, Irvine, CA). Nylon mesh (8 mm diameter) was deposited
onto the RHE tissues before application to ensure even spreading of
the test articles. Triplicate untreated tissues and acitretin vehicle
(octyldodecanol)-treated tissues served as negative controls. This
study was performed twice using n¼ 3 per group, and the data
presented are representative of the two studies.
Cytokine release
Release of IL-1a and IL-8 was quantified in the RHE culture medium
using ELISA kits from R&D Systems (Minneapolis, MN).
Rhino mouse model
Male and female Rhino mice (RHJ/LeJ) were purchased from The
Jackson Laboratory (West Sacramento, CA). All animal handling was
conducted at JAX Services (West Sacramento, CA) in compliance
with the NIH Guide for the Care and Use of Laboratory Animals and
approved by The Jackson Laboratory IACUC. Animals were housed
individually in static caging in a room with yellow lighting
(4500 nm). The mice had access to acidified tap water (pH
2.8–3.2) and Purina Lab Diet 5LL4 ad libitum throughout the study.
Thirty-six mice, 5–7 weeks of age, were treated once daily for 7 days
with the following: acitretin (0.2 or 0.02%) dissolved in dimethyl
isosorbide (DMI, Uniqema, New Castle, DE) containing 0.1%
butylated hydroxytoluene (BHT, Sigma-Aldrich, St Louis, MO);
tretinoin (0.025%) dissolved in DMI containing 0.1% BHT; or
tazarotene (0.1%) cream (n¼ 6 per group). Sham (water treated) and
vehicle controls were included. Coban dressings were applied to the
mice after dosing to prevent rub-off and oral ingestion of the test
agents. On day 7, 5 hours post-dosing, the skin at the site of
application was harvested and cut in half (rostral and caudal
sections) for histological evaluation. Ventral tissue (non-SOA) was
harvested and used as negative control.
Histology
RHE cultures were fixed in 10% formalin (Richard Allen Scientific,
Kalamazoo, MI) and embedded in paraffin. Sections (4 mm) were
stained with H&E or using immunohistochemical staining techni-
ques for K10, K19, or filaggrin. Antibodies and staining kits were
obtained from Vector Laboratories (Burlingame, CA) and used
according to the manufacturer’s recommendations.
Rhino mouse skin specimens were fixed in alcohol formalin and
embedded in paraffin. Three serial sections (4mm) spaced 100 mm
apart were taken and stained with H&E. Histology was carried out by
IDEXX Laboratories (Sacramento, CA).
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Table 1. Utricle diameter of Rhino mice treated topically with various retinoids
Utricle diameter (lm)1
n
Sham
control
Solution
vehicle
Acitretin 0.02%
solution
Acitretin 0.2%
solution
Tretinoin 0.025%
solution
Tazarotene 0.1%
cream
SOA
Female 62 90.4718.5 95.5729.1 2.175.2** 070** 070** 070**
Male 62 123.0712.9 91.4711.6* 67.6714.2* 070** 070** 070**
Non-SOA
Female 3 130.2718.8 125.976.4 98.3721.0 111.2710.1 128.6715.8 116.472.4
Male 3 131.4713.5 109.4720.4 113.376.7 121.8714.6 132.7716.6 105.8731.7
SOA, site of application.
1Various retinoid formulations were administered topically once daily for 7 days to Rhino mice (three males and three females per group). Biopsies from the
dorsal SOA as well as from nontreated ventral sites (non-SOA) were fixed, sectioned, and stained with H&E. Four measurements of the maximum utricle
diameter were taken, averaged, and replicate animal samples averaged with standard deviation calculated. Values are mean7SD.
2Two biopsies (caudal and rostral sides) were collected per SOA per animal.
*Po0.01 versus sham control, Student’s t-test.
**Po0.001 versus sham control, Student’s t-test.
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